BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 10432468)

  • 1. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
    van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
    Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
    Heresco-Levy U; Javitt DC
    Schizophr Res; 2004 Feb; 66(2-3):89-96. PubMed ID: 15061240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
    Goff DC; Tsai G; Levitt J; Amico E; Manoach D; Schoenfeld DA; Hayden DL; McCarley R; Coyle JT
    Arch Gen Psychiatry; 1999 Jan; 56(1):21-7. PubMed ID: 9892252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of D-cycloserine on negative symptoms in schizophrenia.
    Duncan EJ; Szilagyi S; Schwartz MP; Bugarski-Kirola D; Kunzova A; Negi S; Stephanides M; Efferen TR; Angrist B; Peselow E; Corwin J; Gonzenbach S; Rotrosen JP
    Schizophr Res; 2004 Dec; 71(2-3):239-48. PubMed ID: 15474895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
    Tsai G; Lane HY; Yang P; Chong MY; Lange N
    Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.
    Goff DC; Tsai G; Manoach DS; Coyle JT
    Am J Psychiatry; 1995 Aug; 152(8):1213-5. PubMed ID: 7625475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-alanine added to antipsychotics for the treatment of schizophrenia.
    Tsai GE; Yang P; Chang YC; Chong MY
    Biol Psychiatry; 2006 Feb; 59(3):230-4. PubMed ID: 16154544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D-serine added to clozapine for the treatment of schizophrenia.
    Tsai GE; Yang P; Chung LC; Tsai IC; Tsai CW; Coyle JT
    Am J Psychiatry; 1999 Nov; 156(11):1822-5. PubMed ID: 10553752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. D-cycloserine added to clozapine for patients with schizophrenia.
    Goff DC; Tsai G; Manoach DS; Flood J; Darby DG; Coyle JT
    Am J Psychiatry; 1996 Dec; 153(12):1628-30. PubMed ID: 8942463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia.
    Goff DC; Henderson DC; Evins AE; Amico E
    Biol Psychiatry; 1999 Feb; 45(4):512-4. PubMed ID: 10071726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers.
    van Berckel BN; Lipsch C; Gispen-de Wied C; Wynne HJ; Blankenstein MA; van Ree JM; Kahn RS
    Psychopharmacology (Berl); 1998 Jul; 138(2):190-7. PubMed ID: 9718289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
    Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
    Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia.
    Evins AE; Amico E; Posever TA; Toker R; Goff DC
    Schizophr Res; 2002 Jul; 56(1-2):19-23. PubMed ID: 12084415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.
    Goff DC; Herz L; Posever T; Shih V; Tsai G; Henderson DC; Freudenreich O; Evins AE; Yovel I; Zhang H; Schoenfeld D
    Psychopharmacology (Berl); 2005 Apr; 179(1):144-50. PubMed ID: 15502972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study.
    Takiguchi K; Uezato A; Itasaka M; Atsuta H; Narushima K; Yamamoto N; Kurumaji A; Tomita M; Oshima K; Shoda K; Tamaru M; Nakataki M; Okazaki M; Ishiwata S; Ishiwata Y; Yasuhara M; Arima K; Ohmori T; Nishikawa T
    BMC Psychiatry; 2017 Jul; 17(1):249. PubMed ID: 28701225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
    Heresco-Levy U; Ermilov M; Shimoni J; Shapira B; Silipo G; Javitt DC
    Am J Psychiatry; 2002 Mar; 159(3):480-2. PubMed ID: 11870017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
    Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
    JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.